Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept Announces CE-IVD Mark and Availability of its Target Selector™ EGFR Molecular Assay Kit in Europe
Target Selector™ assay kits enable assay developers to leverage Biocept's patented, high-sensitivity technology for the detection of key actional oncogene mutations from both tissue biopsies and blood for liquid biopsy uses SAN DIEGO , April 28, 2020 /PRNewswire/ --  Biocept, Inc .
View HTML
Toggle Summary Biocept Launches Unique Line of Molecular Assay Kits for Detection of Key Oncogene Mutations Based on its Proprietary Target Selector™ Technology Validated for Use in Both Tissue and Blood Samples
SAN DIEGO , April 20, 2020 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the availability of
View HTML
Toggle Summary Biocept Announces Pricing of $10.3 Million Registered Direct Offering Priced At-The-Market
SAN DIEGO , April 14, 2020 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today
View HTML
Toggle Summary Biocept to Begin COVID-19 Testing
Company to provide FDA-approved for EUA testing in its San Diego lab to assist physician clients in the fight against the coronavirus pandemic SAN DIEGO , April 9, 2020 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide
View HTML
Toggle Summary Brazil Patent Granted for Biocept's Target Selector™ Oncogene Mutation Enrichment and Detection Platform
Expands global intellectual property portfolio for highly sensitive methods of detecting cancer biomarkers in circulating tumor DNA (ctDNA) and other genetic alterations of interest; increases Biocept's total patent awards for technologies used in molecular diagnostics to 39 SAN DIEGO , April 9,
View HTML
Toggle Summary Australia Patent Issued for Primer-Switch Mutation Detection and Amplification Platform
Expands Biocept's intellectual property globally for methods of detecting rare mutations, including cancer biomarkers associated with circulating tumor DNA (ctDNA) SAN DIEGO , April 2, 2020 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed
View HTML
Toggle Summary Biocept Enters into Laboratory Services Agreement with Second California-Based Independent Physician Association
Contract with second IPA serving California expands patient access to Biocept's Target Selector™ liquid biopsy testing for the management of patients diagnosed with cancer SAN DIEGO , March 26, 2020 /PRNewswire/ --  Biocept, Inc.  (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests
View HTML
Toggle Summary Biocept Reports 2019 Fourth Quarter and Full Year Financial Results
- Fourth quarter revenues reached a record $1.8 million, up 108% over the fourth quarter of 2018 and up 17% over the third quarter of 2019 - Fourth quarter commercial revenues increased 94% over the fourth quarter of 2018 and increased 11% over the third quarter of 2019 - Fourth quarter cost of
View HTML
Toggle Summary Biocept to Release 2019 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 25, 2020
SAN DIEGO , March 18, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces that it will release financial
View HTML
Toggle Summary Newly Published Data in Journal of Clinical Pathology Provides Clinical Validation for Biocept's Target Selector™ qPCR Assay to Identify Cancer-Associated Mutations
SAN DIEGO , March 9, 2020 /PRNewswire/ --  Biocept, Inc.  (Nasdaq: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the publication of clinical data
View HTML